ReviewGenes & diseases2025
Research progress and the prospect of using single-cell sequencing technology to explore the characteristics of the tumor microenvironment.
Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Single-cell analysis reveals crosstalk between TREM1-positive myeloid cells and cancer-associated fibroblasts in colorectal cancer progression.Journal of gastroenterology · 2026Article
- Obesity and diabetes associated with dysregulation of mevalonate pathway markers and progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.Stem cell research & therapy · 2026Article
- Integrative bioinformatics analysis unveils neuro-cancer crosstalk-related genes and establishes prognostic risk model in Glioblastoma.Scientific reports · 2026Article
- Advances in Colorectal Cancer Cell Biology and Clonal Evolution.International journal of molecular sciences · 2026Review
- Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.Molecular biology reports · 2026Review
- Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026Review
- Decoding the Tumor Microenvironment: Insights and New Targets from Single-Cell Sequencing and Spatial Transcriptomics.Current issues in molecular biology · 2025Review
- Delving Into the Dialogue between Epigenetic Modifications and Immunometabolism in Cancer.Advanced genetics (Hoboken, N.J.) · 2025Article
- Transcriptomic analysis of laser-capture microdissected tumors reveals RAD51AP1 as a tumor-specific marker associated progression from pancreatic intraepithelial neoplasia to invasive pancreatic cancer.Cancer cell international · 2025Article
- Serine metabolism in tumor progression and immunotherapy.Discover oncology · 2025Review
- Single-Cell RNA Sequencing Outperforms Single-Nucleus RNA Sequencing in Analyzing Pancreatic Cell Diversity and Gene Expression in Goats.International journal of molecular sciences · 2025Article
- Comprehensive Integrated Analysis Reveals the Spatiotemporal Microevolution of Cancer Cells in Patients with Bone-Metastatic Prostate Cancer.Biomedicines · 2025Article
- Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In precision cancer therapy, addressing intra-tumor heterogeneity poses a significant obstacle. Due to the heterogeneity of each cell subtype and between cells within the tumor, the sensitivity and resistance of different patients to targeted drugs, chemotherapy,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.